DK3164150T3 - Modificeret von willebrand-faktor - Google Patents

Modificeret von willebrand-faktor Download PDF

Info

Publication number
DK3164150T3
DK3164150T3 DK15814529.2T DK15814529T DK3164150T3 DK 3164150 T3 DK3164150 T3 DK 3164150T3 DK 15814529 T DK15814529 T DK 15814529T DK 3164150 T3 DK3164150 T3 DK 3164150T3
Authority
DK
Denmark
Prior art keywords
modified
willebrand factor
willebrand
factor
Prior art date
Application number
DK15814529.2T
Other languages
English (en)
Inventor
Michael Wilson
Steve Dower
Dallas Hartman
Matthew Hardy
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902532A external-priority patent/AU2014902532A0/en
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Application granted granted Critical
Publication of DK3164150T3 publication Critical patent/DK3164150T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
DK15814529.2T 2014-07-02 2015-07-02 Modificeret von willebrand-faktor DK3164150T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014902532A AU2014902532A0 (en) 2014-07-02 Modified von willebrand factor
PCT/AU2015/050369 WO2016000039A1 (en) 2014-07-02 2015-07-02 Modified von willebrand factor

Publications (1)

Publication Number Publication Date
DK3164150T3 true DK3164150T3 (da) 2021-02-08

Family

ID=55018159

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15814529.2T DK3164150T3 (da) 2014-07-02 2015-07-02 Modificeret von willebrand-faktor

Country Status (11)

Country Link
US (1) US10253088B2 (da)
EP (1) EP3164150B1 (da)
JP (1) JP6676551B2 (da)
KR (1) KR20170026580A (da)
CN (1) CN106659771B (da)
AU (1) AU2015283822B2 (da)
BR (1) BR112016030950A2 (da)
CA (1) CA2953593C (da)
DK (1) DK3164150T3 (da)
ES (1) ES2844232T3 (da)
WO (1) WO2016000039A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10808023B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated von Willebrand factor
WO2017117631A1 (en) * 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
JP7252890B2 (ja) 2016-11-11 2023-04-05 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
DK3641800T3 (da) * 2017-06-22 2024-01-02 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
JP2022538357A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
JPH07306165A (ja) 1994-05-12 1995-11-21 Toshiba Corp Ｘ線検査装置およびｘ線検査補修装置
EP0683389A1 (en) 1994-05-12 1995-11-22 Kabushiki Kaisha Toshiba Laminograph and inspection and repair device using the same
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU3202797A (en) 1996-04-24 1997-11-12 Regents Of The University Of Michigan, The Inactivation resistant factor viii
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
JP4361786B2 (ja) 2001-06-14 2009-11-11 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
ATE463514T1 (de) 2002-04-29 2010-04-15 Sanquin Bloedvoorziening ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)
JPWO2004075293A1 (ja) 2003-02-19 2006-06-01 日立化成工業株式会社 半導体用接着フィルム、これを用いた接着フィルム付金属板、接着フィルム付配線回路及び半導体装置並びに半導体装置の製造方法
KR101085375B1 (ko) 2003-02-26 2011-11-21 넥타르 테라퓨틱스 중합체-인자 ⅷ 부분 콘쥬게이트
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
AU2004309063B2 (en) 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
LT1824988T (lt) 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
WO2006071801A2 (en) 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
JP2008537680A (ja) 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
NZ626945A (en) * 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
EP2814502B1 (en) * 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity

Also Published As

Publication number Publication date
EP3164150A4 (en) 2018-03-07
CN106659771B (zh) 2021-09-24
KR20170026580A (ko) 2017-03-08
CA2953593A1 (en) 2016-01-07
AU2015283822A1 (en) 2017-01-12
CA2953593C (en) 2023-09-26
JP2017521070A (ja) 2017-08-03
WO2016000039A1 (en) 2016-01-07
US20170152300A1 (en) 2017-06-01
JP6676551B2 (ja) 2020-04-08
US10253088B2 (en) 2019-04-09
BR112016030950A2 (pt) 2018-03-27
ES2844232T3 (es) 2021-07-21
AU2015283822B2 (en) 2019-10-03
CN106659771A (zh) 2017-05-10
EP3164150B1 (en) 2020-11-04
EP3164150A1 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3122672T3 (da) Griber
DK3119396T3 (da) Muscarinreceptoragonister
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
DK3006072T3 (da) Karadgang
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3174483T3 (da) Hyporørkonstruktion
DK3164150T3 (da) Modificeret von willebrand-faktor
DE112015001664A5 (de) Betätigungsaktuator
DK3400238T3 (da) Muteret von willebrand faktor
DK3183340T3 (da) Termolabile exonukleaser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
FI20145032A (fi) Nasta
UY4467S (es) Frasco
DE102014000623A8 (de) Halbhohlnietelement
DK3265483T3 (da) Modificeret von Willebrand-faktor med forbedret halveringstid
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
FI20145330A (fi) Immunomääritys